JPMorgan Chase & Co. Has $95.09 Million Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

JPMorgan Chase & Co. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 21.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 482,745 shares of the medical research company’s stock after buying an additional 85,759 shares during the period. JPMorgan Chase & Co. owned about 0.94% of Charles River Laboratories International worth $95,086,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Tortoise Investment Management LLC grew its holdings in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after acquiring an additional 57 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in shares of Charles River Laboratories International during the third quarter worth $32,000. Assetmark Inc. grew its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in Charles River Laboratories International during the 3rd quarter worth $59,000. Finally, Covestor Ltd raised its position in Charles River Laboratories International by 40.9% during the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock worth $65,000 after purchasing an additional 95 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on CRL shares. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research note on Monday, November 18th. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, TD Cowen lifted their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $214.00.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Down 1.1 %

Shares of NYSE:CRL opened at $182.64 on Friday. The firm has a market cap of $9.34 billion, a P/E ratio of 22.86, a PEG ratio of 5.00 and a beta of 1.38. Charles River Laboratories International, Inc. has a 52-week low of $176.48 and a 52-week high of $275.00. The business’s 50 day simple moving average is $192.76 and its two-hundred day simple moving average is $200.46. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same quarter last year, the firm posted $2.72 EPS. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).